文献速递淋巴瘤

突变负荷与效应T细胞基因特征可区分免疫学上不同且临床相关的淋巴瘤亚群

Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets.
PubMed 文献 · Blood Adv · 2017-09-27

基于249例滤泡性淋巴瘤(FL)患者的临床与基因组数据,分析突变负荷和效应T细胞(Teff)基因特征对功能性免疫应答可能性的判断价值。高突变负荷患者中92%伴有高Teff基因表达(P = .001);低突变负荷患者从利妥昔单抗维持治疗中获益显著(HR 0.29,95%CI 0.15-0.54,P < .001)。Teff基因特征可区分「炎症型」与「非炎症型」亚群,炎症型无进展生存期更长(PFS HR 0.39,95%CI 0.21-0.70,P = .002)。

要点

  • 249例FL中突变负荷0–33个突变/Mb(中位6.6),高负荷者92%伴高Teff表达(P = .001)。
  • 低突变负荷FL患者从利妥昔单抗维持治疗中获益显著(HR 0.29,95%CI 0.15-0.54,P < .001)。
  • Teff-high「炎症型」(n = 74)较Teff-low「非炎症型」(n = 75)PFS更长(HR 0.39,95%CI 0.21-0.70,P = .002)。

核心结论

  • 突变负荷与Teff基因表达可能有助于识别与现代免疫治疗相关的免疫学上不同的淋巴瘤亚群。

研究设计与样本

  • 利用249例滤泡性淋巴瘤患者的临床与基因组数据,分析突变负荷和效应T细胞基因特征作为功能性免疫应答可能性的替代指标。

主要发现

  • FL突变负荷估计值在0至33个突变/Mb之间(中位6.6),高突变负荷FL患者中92%伴有高Teff基因表达(P = .001)。
  • 低突变负荷FL患者从利妥昔单抗维持治疗中获益显著(HR 0.29,95%CI 0.15-0.54,P < .001)。
  • Teff基因特征作为连续预测因子具有预后价值(P = .008),并据此将FL患者分为「炎症型」亚群(Teff-high;n = 74)和「非炎症型」亚群(Teff-low;n = 75)。
  • 炎症型FL亚群的无进展生存期更长(PFS HR 0.39,95%CI 0.21-0.70,P = .002)。
  • 炎症型FL肿瘤亚群还高表达其他T细胞特征和反向调节基因,这些也与PFS相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Identifying follicular lymphoma (FL) patients with preexisting antitumor immunity will inform precision medicine strategies for novel cancer immunotherapies. Using clinical and genomic data from 249 FL patients, we determined the clinical impact of mutation load and an effector T-cell (Teff) gene signature as proxies for the likelihood of a functional immune response. The FL mutation load estimate varied between 0 and 33 mutations per Mb (median, 6.6), and 92% of FL patients with a high mutation load had high Teff gene expression (P = .001). The mutation load was associated with a benefit from rituximab maintenance: FL patients with low mutation loads experienced a profound benefit from rituximab maintenance (hazard ratio [HR], 0.29; 95% confidence interval [CI], 0.15-0.54; P < .001). The Teff gene signature was prognostic as a continuous predictor (P = .008), and was used to separate FL patients into 2 groups, an "inflamed" subset (Teff-high; n = 74) and an "uninflamed" subset (Teff-low; n = 75), with longer progression-free survival (PFS) in the inflamed FL subset (PFS HR, 0.39; 95% CI, 0.21-0.70; P = .002). Furthermore, the subset of inflamed FL tumors demonstrated high expression of other T-cell signatures and counterregulatory genes, which also correlate with PFS. Mutation load and Teff gene expression may help identify immunologically distinct lymphoma subsets relevant for modern immunotherapies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bolen CR, McCord R, Huet S, et al. Mutation load and an effector T-cell gene signature may distinguish immunologically distinct and clinically relevant lymphoma subsets. Blood Adv. 2017. PMID: 29296835. doi:10.1182/bloodadvances.2016000786

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。